Nachrichten und Videos - OREXO AB [CBOE] - Seite 2

Orexo and Sobi agree to advance feasibility study with AmorphOX PR Newswire UPPSALA, Sweden, Feb. 12, 2024 Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company´s world-class drug delivery platform, AmorphOX® The feasibility study confirmed that the biomolecule retained its activity after formulation with AmorphOX Orexo has patent applications for AmorphOX formulations relating to biomolecules. UPPSALA, Sweden , Feb. 12, 2024 /PRNewswire/ -- Orexo...

Orexo Interim Report Q4 2023, incl. Full Year Report PR Newswire UPPSALA, Sweden, Feb. 8, 2024 UPPSALA, Sweden , Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 23.4 m (-0.1) Net earnings of SEK -18.6 m (-91.8) US Pharma segment (Zubsolv ® US) net revenues of SEK 151.3 m...

Orexo Interim Report Q4 2023, incl. Full Year Report PR Newswire UPPSALA, Sweden, Feb. 8, 2024 UPPSALA, Sweden , Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 23.4 m (-0.1) Net earnings of SEK -18.6 m (-91.8) US Pharma segment (Zubsolv ® US) net revenues of SEK 151.3 m...

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC PR Newswire UPPSALA, Sweden, Feb. 6, 2024 OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX® The American Academy of Allergy, Asthma & Immunology (AAAAI) is the largest professional medical organization in the United States devoted to the...

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose PR Newswire UPPSALA, Sweden, Nov. 28, 2023 OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Synthetic opioids are behind 91 percent of all fatal opioid overdoses in the US [1 ] Prescription Drug User Fee Act date (PDUFA) set to July 15, 2024 . If...

Orexo Q3 2023 Interim Report PR Newswire UPPSALA, Sweden, Nov. 2, 2023 Big step forward in launching OX124 in the US UPPSALA, Sweden , Nov. 2, 2023 /PRNewswire/ -- Q3 2023 highlights › Total net revenues of SEK 156.1 m (161.0) › EBITDA of SEK -9.5 m (-32.4), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 13.3 m (14.3) › Net earnings of SEK -33.3 m (-26.5) › US Pharma segment (ZUBSOLV® US) net revenues of SEK 140.4 m (150.1), in local...

Orexo Q3 2023 Interim Report PR Newswire UPPSALA, Sweden, Nov. 2, 2023 Big step forward in launching OX124 in the US UPPSALA, Sweden , Nov. 2, 2023 /PRNewswire/ -- Q3 2023 highlights › Total net revenues of SEK 156.1 m (161.0) › EBITDA of SEK -9.5 m (-32.4), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 13.3 m (14.3) › Net earnings of SEK -33.3 m (-26.5) › US Pharma segment (ZUBSOLV® US) net revenues of SEK 140.4 m (150.1), in local...

Orexo announces changes in the company´s Board of Directors PR Newswire UPPSALA, Sweden, Oct. 27, 2023 UPPSALA, Sweden , Oct. 27, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers , Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors. Robin Evers replaces Henrik Kjaer Hansen , who has announced he will resign after having...

Orexo´s Nomination Committee for the Annual General Meeting 2024 PR Newswire UPPSALA, Sweden, Oct. 26, 2023 UPPSALA, Sweden , Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26 , a Nomination Committee has been appointed. The shareholders having appointed members of the Nomination Committee represent approximately 35 percent of the number of votes in the company, based on the latest known shareholder information. The Nomination...

Orexo´s Nomination Committee for the Annual General Meeting 2024 PR Newswire UPPSALA, Sweden, Oct. 26, 2023 UPPSALA, Sweden , Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26 , a Nomination Committee has been appointed. The shareholders having appointed members of the Nomination Committee represent approximately 35 percent of the number of votes in the company, based on the latest known shareholder information. The Nomination...

Report from Orexo´s extraordinary general meeting PR Newswire STOCKHOLM, Oct. 26, 2023 STOCKHOLM , Oct. 26, 2023 /PRNewswire/ -- Election of new member of the board of directors The extraordinary general meeting in Orexo AB (publ) on 26 October 2023 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members. Robin Evers was elected as a new board member. Furthermore, the board member Henrik Kjær Hansen was...

Report from Orexo´s extraordinary general meeting PR Newswire STOCKHOLM, Oct. 26, 2023 STOCKHOLM , Oct. 26, 2023 /PRNewswire/ -- Election of new member of the board of directors The extraordinary general meeting in Orexo AB (publ) on 26 October 2023 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members. Robin Evers was elected as a new board member. Furthermore, the board member Henrik Kjær Hansen was...

Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids PR Newswire UPPSALA, Sweden, Oct. 11, 2023 The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant difference between treatment arms in any pre-specified endpoint Both treatment arms had unexpectedly high rates of treatment response, with no adverse events associated with the use of MODIA A post hoc analysis found...

Notice of Extraordinary General Meeting in Orexo AB (publ) PR Newswire UPPSALA, Sweden, Oct. 3, 2023 UPPSALA, Sweden, Oct. 3, 2023 /PRNewswire/ -- Orexo AB (publ), Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2023 at 15:00 CEST at Advokatfirman Vinge's premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden . Right to participate in the Extraordinary General Meeting and notice of participation A...

Notice of Extraordinary General Meeting in Orexo AB (publ) PR Newswire UPPSALA, Sweden, Oct. 3, 2023 UPPSALA, Sweden , Oct. 3, 2023 /PRNewswire/ -- Orexo AB (publ), Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2023 at 15:00 CEST at Advokatfirman Vinge's premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden . Right to participate in the Extraordinary General Meeting and notice of participation A...

Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose PR Newswire UPPSALA, Sweden, Sept. 18, 2023 OX124 is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effect of the most powerful synthetic opioids, such as fentanyl Synthetic opioids are behind 91 percent of all fatal opioid overdoses in the US [1] If approved, US launch is expected to be initiated late in H2 2024 or early 2025 UPPSALA, Sweden ,...

Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023 PR Newswire UPPSALA, Sweden, Sept. 5, 2023 UPPSALA, Sweden, Sept. 5, 2023 /PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) , today announces the company will participate in Pareto Securities' 14 th Annual Healthcare Conference, that takes place on September 14 , at Hotel At Six, Brunkebergstorg 6, Stockholm, Sweden . On the day, between 3:25-3:45 CET (room Event Large), Robert Rönn, SVP and Head of R&D,...

Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023 PR Newswire UPPSALA, Sweden, Sept. 5, 2023 UPPSALA, Sweden , Sept. 5, 2023 /PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) , today announces the company will participate in Pareto Securities' 14 th Annual Healthcare Conference, that takes place on September 14 , at Hotel At Six, Brunkebergstorg 6, Stockholm, Sweden . On the day, between 3:25-3:45 CET (room Event Large), Robert Rönn, SVP and Head of R&D,...

Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product PR Newswire UPPSALA, Sweden, Aug. 29, 2023 UPPSALA, Sweden , Aug. 29, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform. Orexo continues to strengthen its patent portfolio...

Orexo's patent win for ZUBSOLV® appealed PR Newswire UPPSALA, Sweden, July 24, 2023 UPPSALA, Sweden , July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc. (collectively "Sun") have appealed the patent litigation decision issued by the US District Court for the District of New Jersey relating to Orexo's patents protecting...